Zhengye Biotechnology Holding, a Chinese provider of veterinary vaccines with a focus on livestock, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering.
Through its operating entity, the company focuses on the research, development, manufacturing, and sale of veterinary vaccines, with an emphasis on vaccines for livestock. Its product portfolio currently contains 43 veterinary vaccines, covering all major vaccines for livestock like swine and cattle, and it is also developing vaccines for household animals like dogs. Zhengye Biotechnology's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt.
The Jilin, China-based company was founded in 2004 and booked $35 million in sales for the 12 months ended June 30, 2023. It plans to list on the Nasdaq under the symbol ZYBT. Zhengye Biotechnology Holding filed confidentially on August 4, 2023. Tiger Brokers is the sole bookrunner on the deal. No pricing terms were disclosed.
